Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil ...

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a ...

Central Pacific Bank Trust Division lessened its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 82.3% in the 4th ...

Here's why Amgen increased its land holdings in New Albany, even though the pharma giant has plenty of room for expansion on ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Prothena (PRTA – Research Report) today and set a price target of $58.00. The ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today. The company’s ...

Amgen stock gains on drug results of Novo Nordisk ... Shares of the pharmaceutical corporation have been trending lower since achieving an all-time high in July of this year above $346.